Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center

Articles by Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center

Renal Cell Carcinoma: Future Evolutions in Care

ByBrian I. Rini, MD, Cleveland Clinic,Eric Jonasch, MD, University of Texas MD Anderson Cancer Center,Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center,Bruno R. Bastos, MD, Miami Cancer Institute ,Stephanie Berg, DO

July 24th 2023

Shared insight on the evolving state of renal cell carcinoma management and hope for future growth in the treatment landscape.

Selecting Optimal Therapy for Advanced Non-Clear Cell RCC

ByDiscussant: Brian I. Rini, MD, Cleveland Clinic,Eric Jonasch, MD, University of Texas MD Anderson Cancer Center,Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center,Bruno R. Bastos, MD, Miami Cancer Institute ,Stephanie Berg, DO

July 24th 2023

Focusing their discussion on a real-world patient scenario, expert panelists discuss treatment options in the setting of advanced non-clear cell renal cell carcinoma.

Relapsed/Refractory Clear Cell RCC: Novel Treatment Strategies

ByBrian I. Rini, MD,Eric A. Jonasch, MD, MD Anderson Cancer Center,Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center,Bruno R. Bastos, MD, Miami Cancer Institute ,Stephanie Berg, DO

July 17th 2023

Switching their focus to relapsed/refractory advanced clear cell renal cell carcinoma, key opinion leaders review treatment options in this setting.

Second-Line Treatment Armamentarium in Clear Cell RCC

ByBrian I. Rini, MD,Eric A. Jonasch, MD, MD Anderson Cancer Center,Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center,Bruno R. Bastos, MD, Miami Cancer Institute ,Stephanie Berg, DO

July 17th 2023

Comprehensive insight to treatment options available in the second-line setting of advanced clear cell renal cell carcinoma.

Rationale Behind Discontinuing IO Therapy in Clear Cell RCC

ByBrian I. Rini, MD,Eric A. Jonasch, MD, MD Anderson Cancer Center,Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center,Bruno R. Bastos, MD, Miami Cancer Institute ,Stephanie Berg, DO

July 10th 2023

Focused discussion on the rationale behind discontinuing (or continuing) immunotherapy for patients with advanced clear cell renal cell carcinoma.

Selecting Therapy for a Real-World Patient With Clear Cell RCC

ByBrian I. Rini, MD,Eric A. Jonasch, MD, MD Anderson Cancer Center,Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center,Bruno R. Bastos, MD, Miami Cancer Institute ,Stephanie Berg, DO

July 10th 2023

Centering discussion on a patient scenario of advanced clear cell renal cell carcinoma, panelists reflect on how they would approach selecting first-line therapy.